Exemestane
Information
- Drug Name
- Exemestane
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| breast cancer | PGR EXPRESSION PGR EXPRESSION | B |
Predictive
|
Does Not Support
|
N/A | Somatic | 4 | 21422407 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In patients with breast cancer, those with low exp... | PGR | PGR EXPRESSION PGR EXPRESSION | N/A | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03179904 | Active, not recruiting | Phase 2 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | August 3, 2017 | July 30, 2024 |
| NCT02947685 | Active, not recruiting | Phase 3 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | June 21, 2017 | July 31, 2026 |
| NCT04059484 | Active, not recruiting | Phase 2 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | October 22, 2019 | September 30, 2024 |
| NCT00066690 | Active, not recruiting | Phase 3 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | December 17, 2003 | December 2025 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT02188745 | Active, not recruiting | Phase 2 | ER Reactivation Therapy for Breast Cancer | March 11, 2016 | October 2024 |
| NCT03280563 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | December 26, 2017 | December 31, 2024 |
| NCT00066703 | Active, not recruiting | Phase 3 | Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | November 3, 2003 | December 2025 |
| NCT02115282 | Active, not recruiting | Phase 3 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | March 29, 2014 | June 14, 2024 |
| NCT03554044 | Active, not recruiting | Phase 1 | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | February 5, 2020 | April 30, 2025 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT02007512 | Active, not recruiting | Phase 2 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | December 13, 2013 | June 28, 2024 |
| NCT03219476 | Active, not recruiting | Phase 2 | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | February 5, 2017 | July 1, 2024 |
| NCT04572295 | Active, not recruiting | Phase 1 | A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer | October 9, 2020 | December 31, 2024 |
| NCT01674140 | Active, not recruiting | Phase 3 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | September 12, 2013 | January 2030 |
| NCT01272037 | Active, not recruiting | Phase 3 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | January 15, 2011 | October 1, 2032 |
| NCT03300557 | Active, not recruiting | Phase 2 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | November 15, 2017 | June 30, 2024 |
| NCT04300790 | Active, not recruiting | Phase 2 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | October 23, 2020 | June 30, 2026 |
| NCT00310180 | Active, not recruiting | Phase 3 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | April 7, 2006 | September 30, 2030 |
| NCT00432172 | Completed | Phase 2 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | April 24, 2007 | September 1, 2010 |
| NCT00525096 | Completed | Phase 3 | Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | July 2003 | December 2004 |
| NCT00649090 | Completed | Phase 4 | A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer | March 2005 | April 2007 |
| NCT00659373 | Completed | Phase 3 | Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 | December 2007 | April 2016 |
| NCT00676663 | Completed | Phase 2 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer | June 13, 2008 | November 26, 2012 |
| NCT00719966 | Completed | Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer | September 18, 2008 | January 24, 2020 | |
| NCT00728949 | Completed | Phase 2 | A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | August 2008 | February 2015 |
| NCT00810797 | Completed | Phase 2 | Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer | December 2, 2008 | June 26, 2019 |
| NCT00863655 | Completed | Phase 3 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole | June 3, 2009 | December 4, 2014 |
| NCT00893061 | Completed | Phase 3 | Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer | March 16, 2009 | November 26, 2014 |
| NCT04659551 | Completed | Phase 2 | Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | October 5, 2017 | May 25, 2020 |
| NCT00010010 | Completed | Phase 2 | Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer | June 2000 | |
| NCT00016432 | Completed | Phase 3 | Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen | May 2001 | February 2011 |
| NCT00031889 | Completed | Phase 2 | Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer | August 2001 | June 2002 |
| NCT00032136 | Completed | Phase 3 | Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer | December 2001 | April 2009 |
| NCT00038103 | Completed | Phase 2 | Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen | January 2002 | March 2008 |
| NCT00038467 | Completed | Phase 3 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | February 1998 | March 2013 |
| NCT00065325 | Completed | Phase 3 | The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer | August 2003 | September 2014 |
| NCT00066573 | Completed | Phase 3 | Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer | June 6, 2003 | January 6, 2012 |
| NCT00066586 | Completed | N/A | Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer | August 1, 2001 | February 10, 2009 |
| NCT00073073 | Completed | Phase 2 | Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer | November 2003 | December 2011 |
| NCT00083174 | Completed | Phase 3 | Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer | December 3, 2004 | January 22, 2018 |
| NCT00128843 | Completed | Phase 2 | Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | August 2001 | October 2014 |
| NCT00143390 | Completed | Phase 3 | Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer | April 2005 | December 2010 |
| NCT00201773 | Completed | Phase 2 | Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer | July 2003 | June 2011 |
| NCT00201864 | Completed | Phase 2 | Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer | September 2005 | February 2014 |
| NCT00261027 | Completed | Phase 2 | Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer | January 2003 | September 2007 |
| NCT00265759 | Completed | Phase 3 | Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | January 2006 | November 27, 2019 |
| NCT00279448 | Completed | Phase 3 | Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer | January 2002 | June 2009 |
| NCT00919399 | Completed | Phase 2 | Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | January 2002 | June 2006 |
| NCT00932165 | Completed | Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin | December 2004 | November 2008 | |
| NCT00933309 | Completed | Phase 1 | The Impact of Obesity and Obesity Treatments on Breast Cancer | July 2009 | August 2012 |
| NCT00941330 | Completed | Phase 2 | Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | July 2009 | May 2015 |
| NCT00944918 | Completed | Phase 3 | Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) | December 2008 | June 2011 |
| NCT01151046 | Completed | Phase 2 | Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer | June 2010 | September 2014 |
| NCT01153672 | Completed | N/A | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | November 2010 | August 11, 2016 |
| NCT01202591 | Completed | Phase 1/Phase 2 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients | December 2010 | October 2014 |
| NCT01234857 | Completed | Phase 2 | A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | September 17, 2010 | October 15, 2013 |
| NCT01331421 | Completed | N/A | Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions | July 2004 | August 2004 |
| NCT01331434 | Completed | N/A | Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions | October 2004 | October 2004 |
| NCT01331447 | Completed | N/A | Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions | May 2004 | May 2004 |
| NCT01381874 | Completed | Phase 2 | A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy | August 24, 2011 | August 8, 2018 |
| NCT01385280 | Completed | N/A | Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer | February 2011 | October 2013 |
| NCT01553903 | Completed | Phase 4 | Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not | December 2011 | May 2013 |
| NCT01594216 | Completed | Phase 2 | Ruxolitinib in Estrogen Receptor Positive Breast Cancer | April 2012 | April 9, 2016 |
| NCT01594398 | Completed | Phase 1 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | May 2012 | May 2014 |
| NCT01597193 | Completed | Phase 1 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | April 30, 2012 | January 22, 2018 |
| NCT01605396 | Completed | Phase 2 | A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | July 4, 2012 | March 15, 2018 |
| NCT01626222 | Completed | Phase 3 | 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | June 2012 | November 2013 |
| NCT01664754 | Completed | Phase 1 | Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer | September 7, 2012 | January 11, 2019 |
| NCT01698918 | Completed | Phase 2 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | March 7, 2013 | January 13, 2021 |
| NCT01720602 | Completed | N/A | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | November 2012 | January 2020 |
| NCT01743560 | Completed | Phase 4 | An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis | January 31, 2013 | August 15, 2016 |
| NCT01783444 | Completed | Phase 2 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | February 26, 2013 | July 30, 2018 |
| NCT01814397 | Completed | Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients | July 2009 | February 2013 | |
| NCT01831076 | Completed | Phase 2 | Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | April 2002 | January 6, 2022 |
| NCT01857193 | Completed | Phase 1 | Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | September 6, 2013 | April 16, 2020 |
| NCT01870505 | Completed | Phase 1 | BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer | May 2013 | February 28, 2022 |
| NCT01938846 | Completed | Phase 1 | BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | September 5, 2013 | June 22, 2017 |
| NCT01963481 | Completed | Phase 2 | Exemestane and Cyclophosphamide for Metastatic Breast Cancer | September 2013 | October 1, 2017 |
| NCT01965080 | Completed | Phase 2 | Exemestane in Advanced and Recurrent Endometrial Carcinoma | March 2004 | February 2009 |
| NCT01989780 | Completed | Phase 2 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | January 2014 | June 2019 |
| NCT02028364 | Completed | Phase 2 | Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women | January 12, 2014 | August 9, 2021 |
| NCT02028507 | Completed | Phase 3 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | March 13, 2014 | January 11, 2021 |
| NCT02049957 | Completed | Phase 2 | Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | February 13, 2014 | June 29, 2018 |
| NCT02069093 | Completed | Phase 2 | Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | May 2014 | March 2016 |
| NCT02077933 | Completed | Phase 1 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | May 14, 2014 | April 12, 2019 |
| NCT02123823 | Completed | Phase 1 | BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | May 15, 2014 | December 14, 2021 |
| NCT02248571 | Completed | Phase 4 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | August 2014 | September 30, 2017 |
| NCT02258451 | Completed | Phase 2 | Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer | June 4, 2015 | October 28, 2022 |
| NCT02291913 | Completed | Phase 2 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | December 18, 2014 | January 31, 2019 |
| NCT02392611 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | March 16, 2015 | October 11, 2017 |
| NCT02482753 | Completed | Phase 3 | Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer | July 2015 | February 2021 |
| NCT02549430 | Completed | Phase 2 | To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | October 2012 | February 9, 2017 |
| NCT02598557 | Completed | Phase 2 | Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | December 6, 2016 | February 2, 2023 |
| NCT02623751 | Completed | Phase 1 | Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | November 2015 | October 2020 |
| NCT02648477 | Completed | Phase 2 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | March 28, 2016 | December 30, 2023 |
| NCT02666105 | Completed | Phase 2 | Exemestane in Post-Menopausal Women With NSCLC | September 27, 2018 | February 28, 2022 |
| NCT02732119 | Completed | Phase 1/Phase 2 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. | June 14, 2016 | February 25, 2020 |
| NCT02820961 | Completed | Phase 1 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | June 29, 2016 | July 12, 2021 |
| NCT02833155 | Completed | Phase 1 | Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | August 29, 2016 | July 18, 2018 |
| NCT02871791 | Completed | Phase 1/Phase 2 | Palbociclib With Everolimus + Exemestane In BC | August 24, 2016 | September 2021 |
| NCT02894398 | Completed | Phase 2 | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | September 6, 2016 | February 15, 2023 |
| NCT03176238 | Completed | Phase 3 | Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | March 29, 2013 | January 29, 2019 |
| NCT03272477 | Completed | Phase 2 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | October 5, 2017 | March 4, 2024 |
| NCT03291886 | Completed | Phase 2 | Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | September 22, 2017 | March 26, 2021 |
| NCT03312738 | Completed | Phase 2 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | September 15, 2017 | April 25, 2022 |
| NCT03555877 | Completed | Phase 2 | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | March 15, 2018 | July 21, 2022 |
| NCT03659136 | Completed | Phase 2 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | November 28, 2018 | May 11, 2022 |
| NCT03691493 | Completed | Phase 2 | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | February 8, 2019 | October 13, 2022 |
| NCT04129216 | Completed | Phase 2 | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | February 20, 2019 | November 10, 2022 |
| NCT04465097 | Completed | Phase 2 | Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer | July 8, 2020 | October 1, 2023 |
| NCT00002777 | Completed | Phase 3 | Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer | May 1996 | |
| NCT06223698 | Not yet recruiting | Phase 3 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer | May 2, 2024 | May 2, 2035 |
| NCT06380751 | Not yet recruiting | Phase 3 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | April 18, 2024 | July 18, 2030 |
| NCT06179303 | Not yet recruiting | Phase 2 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | July 6, 2024 | June 1, 2026 |
| NCT06428396 | Not yet recruiting | Phase 2 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | June 26, 2024 | May 24, 2028 |
| NCT05774951 | Recruiting | Phase 3 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | March 31, 2023 | May 29, 2036 |
| NCT04975308 | Recruiting | Phase 3 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | October 4, 2021 | August 31, 2027 |
| NCT05891093 | Recruiting | Phase 3 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | June 1, 2023 | May 31, 2031 |
| NCT04985266 | Recruiting | Phase 2 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | March 30, 2022 | September 1, 2030 |
| NCT05952557 | Recruiting | Phase 3 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | October 5, 2023 | May 6, 2037 |
| NCT06001762 | Recruiting | Phase 2 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | October 5, 2023 | January 1, 2027 |
| NCT06075953 | Recruiting | Phase 2 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | February 14, 2024 | November 2033 |
| NCT06016738 | Recruiting | Phase 3 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | November 16, 2023 | September 30, 2027 |
| NCT05514054 | Recruiting | Phase 3 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | October 4, 2022 | March 15, 2032 |
| NCT02476786 | Recruiting | Phase 2 | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | January 17, 2017 | January 31, 2030 |
| NCT05607004 | Recruiting | Phase 2 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | February 14, 2023 | September 2026 |
| NCT05467891 | Recruiting | Phase 2 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | September 13, 2022 | December 2027 |
| NCT06105632 | Recruiting | Phase 3 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | January 9, 2024 | December 14, 2028 |
| NCT05306340 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | August 3, 2022 | March 31, 2026 |
| NCT06169124 | Suspended | Phase 2 | Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors | February 8, 2024 | May 31, 2027 |
| NCT05827081 | Suspended | Phase 3 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | February 28, 2024 | September 20, 2030 |
| NCT04460807 | Terminated | Phase 3 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer | February 13, 2020 | April 27, 2023 |
| NCT00793546 | Terminated | Phase 2 | Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | February 2009 | June 2010 |
| NCT03220178 | Terminated | Phase 4 | Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | July 24, 2017 | December 7, 2021 |
| NCT00674557 | Terminated | Phase 2 | Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer | June 2008 | March 2009 |
| NCT00194792 | Terminated | Phase 2 | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | August 2005 | July 2011 |
| NCT00040014 | Terminated | Phase 2 | Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women | June 2002 | December 2006 |
| NCT00066807 | Terminated | Phase 3 | Premenopausal Endocrine Responsive Chemotherapy Trial | August 2003 | December 2006 |
| NCT00905021 | Terminated | Phase 1/Phase 2 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer | March 2010 | February 2012 |
| NCT04869943 | Terminated | Phase 3 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | October 12, 2021 | January 9, 2024 |
| NCT00573755 | Terminated | Phase 2 | Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer | December 2007 | April 2013 |
| NCT00810706 | Terminated | Phase 3 | Adjuvant Post-Tamoxifen Exemestane Trial | April 2001 | November 2005 |
| NCT01303679 | Terminated | Phase 3 | 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer | June 2010 | May 2018 |
| NCT00417885 | Terminated | Phase 1/Phase 2 | A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer | June 2007 | July 2009 |
| NCT02983604 | Terminated | Phase 1/Phase 2 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | January 10, 2017 | July 19, 2018 |
| NCT00372996 | Terminated | Phase 2 | Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer | February 2007 | June 2014 |
| NCT01627067 | Terminated | Phase 2 | Exemestane-RAD001-Metformin | September 2012 | February 1, 2019 |
| NCT01149356 | Terminated | Phase 1 | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | October 2010 | April 2013 |
| NCT04666805 | Unknown status | Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast | July 1, 2020 | January 15, 2021 | |
| NCT02467686 | Unknown status | Phase 4 | Breast Cancer, Sexuality and Black Cohosh | January 2014 | December 2017 |
| NCT00902954 | Unknown status | Phase 3 | Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer | March 2008 | June 2011 |
| NCT04852081 | Unknown status | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | January 1, 2021 | December 1, 2021 | |
| NCT00931450 | Unknown status | Phase 1/Phase 2 | Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer | March 2009 | |
| NCT02592746 | Unknown status | Phase 2 | A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | June 2016 | June 2021 |
| NCT02676986 | Unknown status | Phase 2 | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer | August 2015 | March 2020 |
| NCT02689921 | Unknown status | Phase 2 | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer | April 2016 | December 2018 |
| NCT02765373 | Unknown status | Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients | January 2015 | ||
| NCT01431053 | Unknown status | Phase 2 | Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer | July 2011 | July 2014 |
| NCT02917005 | Unknown status | Phase 2 | PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer | May 7, 2019 | December 2023 |
| NCT01648608 | Unknown status | Phase 2/Phase 3 | Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer | January 2012 | December 2013 |
| NCT01655004 | Unknown status | N/A | Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | August 2012 | August 2018 |
| NCT00253422 | Unknown status | Phase 3 | Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | March 2004 | |
| NCT03538171 | Unknown status | Phase 3 | Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer | May 15, 2018 | March 2023 |
| NCT00688194 | Unknown status | Phase 3 | Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | May 2008 | |
| NCT02025712 | Unknown status | Phase 2 | Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer | ||
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT00687648 | Unknown status | Phase 2 | Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | May 2008 | |
| NCT04389424 | Unknown status | Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer | September 1, 2017 | January 30, 2022 | |
| NCT00003418 | Unknown status | Phase 3 | Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer | February 1998 | |
| NCT00541086 | Unknown status | Phase 3 | Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery | March 2007 | July 2020 |
| NCT02404051 | Unknown status | Phase 3 | Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | December 2015 | January 2019 |
| NCT01658176 | Withdrawn | Phase 2 | Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer | January 2013 | April 2015 |
| NCT01240941 | Withdrawn | Phase 2 | Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer | February 2011 | December 2012 |
| NCT00057993 | Withdrawn | Phase 2 | Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer | July 2002 | August 2004 |
| NCT01240928 | Withdrawn | Phase 1 | MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer | ||
| NCT00080613 | Withdrawn | Phase 2 | Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | ||
| NCT01005641 | Withdrawn | Phase 2 | ELBA: Exemestane and Lapatinib in Advanced Breast Cancer | December 2009 | March 2012 |
| NCT03238703 | Withdrawn | Phase 4 | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | September 1, 2018 | March 14, 2025 |